Trials / Terminated
TerminatedNCT02575807
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Aduro Biotech, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207, epacadostat (IDO), and pembrolizumab (pembro). The purpose of this study is to find out how safe it is to give the investigational drugs to women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer and if it helps patients with these types of cancer live longer or can help shrink or slow the growth of cancer.
Conditions
- Platinum-resistant Ovarian Cancer
- Platinum-resistant Fallopian Cancer
- Platinum-resistant Peritoneal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CRS-207 | via IV infusion |
| DRUG | Epacadostat | PO BID |
| BIOLOGICAL | Pembrolizumab | via IV infusion |
Timeline
- Start date
- 2016-03-08
- Primary completion
- 2018-04-26
- Completion
- 2018-05-08
- First posted
- 2015-10-15
- Last updated
- 2019-04-04
- Results posted
- 2019-04-04
Locations
12 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02575807. Inclusion in this directory is not an endorsement.